View Older Stories View More Recent Stories

Dec 16, 2022 07:30AM Regeneron (REGN), Sanofi (SNY) Announces Dupixent Recommended for EU Approval by the CHMP for the Treatment of Eosinophilic Esophagitis
Dec 16, 2022 07:29AM Dupixent® (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Eosinophilic Esophagitis
Dec 15, 2022 05:47AM Regeneron (REGN) and Sanofi (SNY) Announce EU Approval of Dupixent for Prurigo Nodularis
Dec 15, 2022 12:59AM Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Prurigo Nodularis
Dec 12, 2022 05:30PM Odronextamab (CD20xCD3) Demonstrates High and Durable Complete Response Rate among Patients with Relapsed/Refractory Follicular Lymphoma in Pivotal Phase 2 Trial
Dec 12, 2022 10:02AM Regeneron (REGN) Announces Linvoseltamab Initial Pivotal Phase 2 Data Show Clinically Meaningful Responses in Patients with Heavily Pre-treated Multiple Myeloma
Dec 12, 2022 10:00AM Linvoseltamab (BCMAxCD3) Initial Pivotal Phase 2 Data Show Clinically Meaningful Responses in Patients with Heavily Pre-treated Multiple Myeloma
Dec 12, 2022 07:30AM Regeneron Named on Dow Jones Sustainability World Index for Fourth Consecutive Year
Dec 12, 2022 06:51AM Regeneron (REGN) announces positive early trial of data of odronextamab in patients with relapsed/refractory diffuse large B-cell lymphoma at ASH
Dec 11, 2022 10:30AM Pivotal Odronextamab (CD20xCD3) Phase 2 Data in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Debut at ASH
Dec 1, 2022 07:00AM Regeneron ESMO IO Presentations Highlight Potential of Fianlimab and Libtayo® (cemiplimab) in Multiple Solid Tumor Types
Nov 30, 2022 08:06AM Regeneron (REGN) Announces Evkeeza sBLA for Children with Ultra-rare Inherited Form of High Cholesterol Accepted for FDA Priority Review
Nov 30, 2022 08:05AM Evkeeza® (evinacumab-dgnb) sBLA for Children with Ultra-rare Inherited Form of High Cholesterol Accepted for FDA Priority Review
Nov 22, 2022 07:01AM Regeneron (REGN) Announces Libtayo Approved in EU for Metastatic Cervical Cancer Irrespective of PD-L1 Expression Level or Tumor Histology
Nov 22, 2022 07:00AM Libtayo® (cemiplimab) Approved by the European Commission as the First Immunotherapy in Second Line Recurrent or Metastatic Cervical Cancer Irrespective of PD-L1 Expression Level or Tumor Histology
Nov 17, 2022 07:01AM Regeneron (REGN) and CytomX (CTMX) Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
Nov 17, 2022 07:00AM CytomX and Regeneron Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
Nov 17, 2022 07:00AM Regeneron and CytomX Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
Nov 11, 2022 06:59AM Regeneron (REGN) Announces Dupixent Recommended for EU Approval by the CHMP
Nov 11, 2022 06:59AM Dupixent® (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Prurigo Nodularis
Nov 8, 2022 04:45PM Regeneron (REGN) Announces FDA Approval of Libtay in Combination with Chemotherapy for Treatment for Advanced Non-small Cell Lung Cancer (NSCLC)
Nov 8, 2022 04:41PM Libtayo® (cemiplimab-rwlc) in Combination with Chemotherapy Approved by the FDA as First-line Treatment for Advanced Non-small Cell Lung Cancer (NSCLC)
Nov 4, 2022 07:30PM Aflibercept 8 mg Late-breaking Data Presented at Retina Society in Diabetic Macular Edema and Wet Age-related Macular Degeneration
Nov 3, 2022 04:05PM Regeneron Announces Investor Conference Presentations
Nov 3, 2022 09:00AM Regeneron Presents New Data at ASH from Advancing Hematology Pipeline across Multiple Blood Cancers and Disorders
Nov 3, 2022 06:30AM Regeneron Reports Third Quarter 2022 Financial and Operating Results
Oct 28, 2022 08:03AM Regeneron's (REGN) Inmazeb Wins 2022 Prix Galien USA Best Biotechnology Product Award
Oct 28, 2022 08:00AM Inmazeb™ (atoltivimab, maftivimab, and odesivimab-ebgn) Wins Prestigious 2022 Prix Galien USA Best Biotechnology Product Award
Oct 21, 2022 07:00AM Regeneron (REGN) Granted Six Month US Pediatric Exclusivity for EYLEA
Oct 21, 2022 07:00AM Regeneron Receives Six Months of U.S. Pediatric Exclusivity for EYLEA® (aflibercept) Injection
Oct 17, 2022 08:02AM Immune-Onc Therapeutics Initiates Expansion Cohorts for IO-108 and Enters into Clinical Supply Agreement with Regeneron (REGN)
Oct 17, 2022 08:00AM Immune-Onc Therapeutics Initiates Expansion Cohorts for IO-108 and Enters into Clinical Supply Agreement with Regeneron
Oct 14, 2022 07:05AM Regeneron (REGN) Announces Positive CHMP Opinion for Libtayo
Oct 14, 2022 07:04AM Libtayo® (cemiplimab) Receives Positive CHMP Opinion Recommending Approval to Treat Advanced Cervical Cancer
Oct 12, 2022 07:02AM Regeneron (REGN) Announces EYLEA Injection sBLA for Treatment of Retinopathy of Prematurity Accepted for FDA Priority Review
Oct 12, 2022 07:00AM EYLEA® (aflibercept) Injection sBLA for Treatment of Retinopathy of Prematurity (ROP) Accepted for FDA Priority Review
Oct 11, 2022 12:59AM Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old
Oct 4, 2022 04:00PM Regeneron to Report Third Quarter 2022 Financial and Operating Results and Host Conference Call and Webcast on November 3, 2022
Oct 3, 2022 07:02AM Regeneron (REGN) Appoints Craig B. Thompson to its Board
Oct 3, 2022 07:00AM Regeneron Elects Dr. Craig B. Thompson to Board of Directors
Sep 30, 2022 05:04PM Aflibercept 8 mg Positive Pivotal Results in Diabetic Macular Edema and Wet Age-Related Macular Degeneration Presented at AAO
Sep 28, 2022 05:46PM Regeneron (REGN), Sanofi (SNY) Announce FDA Approval for Dupixent to Treat Prurigo Nodularis
Sep 28, 2022 05:44PM Dupixent® (dupilumab) Approved by FDA as the First and Only Treatment Indicated for Prurigo Nodularis
Sep 16, 2022 07:16AM Regeneron (REGN) and Intellia (NTLA) Report Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001
Sep 16, 2022 07:15AM Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis
Sep 16, 2022 07:15AM Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis
Sep 16, 2022 05:53AM Regeneron (REGN) Reports Publication of Positive Dupixent Data in Children 6 Month - 5 Years Old
Sep 15, 2022 06:38PM Positive Dupixent® (dupilumab) Phase 3 Data in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis Published in The Lancet
Sep 15, 2022 07:00AM Regeneron (REGN) and Alnylam (ALNY) Report Strong Data from Ongoing Phase 1 Study of ALN-HSD
Sep 15, 2022 07:00AM Alnylam and Regeneron Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers
View More Recent Stories View Older Stories